Gaurav Lakhanpal, MD
Interventional Cardiology · Greenbelt, MDNPI 1013172907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,280 of the $9,712 with a category attached, or 85.3%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 301 payments — averaging $32.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$2K
- Johnson & Johnson$2K
- Cardiovascular Systems Inc.$1K
- Angiodynamics, Inc.$1K
- Medtronic$914
- BD$252
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1,39114%
- Food & beverage$8,28085%
- Education$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 48 | $2,314 |
| Johnson & Johnson | 92 | $2,218 |
| Cardiovascular Systems Inc. | 12 | $1,277 |
| Angiodynamics, Inc. | 60 | $1,080 |
| Medtronic | 26 | $914 |
| BD | 5 | $252 |
| Boston Scientific | 4 | $225 |
| E.r. Squibb & Sons, L.L.C. | 12 | $220 |
| Tactile Systems Technology Inc | 9 | $210 |
| Biocompatibles, Inc. | 1 | $149 |
| Philips North America LLC | 3 | $146 |
| Teva Pharmaceuticals USA, Inc. | 1 | $139 |
| Cook Medical LLC | 4 | $64 |
| Progenacare Global, LLC | 1 | $63 |
| Globus Medical | 3 | $51 |
| Nevro Corp. | 2 | $36 |
| Pfizer | 2 | $36 |
| Cashflow Solutions, LLC | 2 | $36 |
| Penumbra, Inc. | 1 | $34 |
| Biowound Solutions, Inc. | 1 | $30 |
| W. L. Gore & Associates, Inc. | 2 | $30 |
| Next Science LLC | 1 | $26 |
| Novo Nordisk | 1 | $23 |
| Triad Life Sciences Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| ETS Wound Care LLC | 1 | $20 |
| Shockwave Medical, Inc | 1 | $19 |
| Silk Road Medical, Inc. | 1 | $18 |
| Convatec Inc. | 1 | $14 |
| Lemaitre Vascular, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Peripheral Orbital Atherectomy System$1,063
- RotarexS 6 F x 135 cm$762
- VENOVO$548
- XARELTO$374
- Abre$274
- VARITHENA$149
- AJOVY$139
- Varithena Administration Pack$133
- VenaSeal$128
- (5028) IGT Devices Systems Undivided$101
How this compares
$9,712 in reported general payments places this provider in the 55th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 117 | $92,260 |
| EliquisApixaban | 33 | $24,341 |
| ClopidogrelClopidogrel Bisulfate | 93 | $1,278 |
| Ezetimibe | 15 | $840 |
| Atorvastatin Calcium | 43 | $623 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 28 | $156 |
| Tramadol Hcl | 24 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $2,218 | $92,260117 claims |
| PfizerEliquis | $36 | $24,34133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Greenbelt
- Vinay SatwahGreenbelt$679K
- Mohammad SarfaraziGreenbelt$4K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
- Ali TabrizchiBel Air$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.